Infinity Pharmaceuticals (INFI) Stock Forecast, Price Target & Predictions
INFI Stock Forecast
Infinity Pharmaceuticals stock forecast is as follows: a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
INFI Analyst Ratings
Buy
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Nov 16, 2022 | B. Riley Securities | - | Neutral | Downgrade |
May 23, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Jul 28, 2021 | Wells Fargo | - | Overweight | Upgrade |
10
Infinity Pharmaceuticals Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
SQZ | SQZ Bio | $0.44 | $400.00 | 90809.09% | Buy |
ADTX | Aditxt | $0.49 | $160.00 | 32553.06% | - |
INFI | Infinity Pharmaceuticals | $0.01 | $3.00 | 29900.00% | Buy |
KRON | Kronos Bio | $0.95 | $7.63 | 703.16% | Buy |
CTMX | CytomX Therapeutics | $1.01 | $5.77 | 471.29% | Buy |
DRMA | Dermata Therapeutics | $1.22 | $6.00 | 391.80% | Buy |
NUVB | Nuvation Bio | $2.29 | $6.75 | 194.76% | Buy |
TIL | Instil Bio | $27.63 | $78.25 | 183.21% | Hold |
TRVI | Trevi Therapeutics | $3.04 | $8.00 | 163.16% | Buy |
ERAS | Erasca | $2.87 | $7.00 | 143.90% | Buy |
NXTC | NextCure | $1.31 | $3.00 | 129.01% | Buy |
CCCC | C4 Therapeutics | $6.45 | $13.50 | 109.30% | Buy |
ASMB | Assembly Biosciences | $16.98 | $35.50 | 109.07% | Buy |
LYRA | Lyra Therapeutics | $0.26 | $0.50 | 92.31% | Hold |
EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
INFI Forecast FAQ
Is Infinity Pharmaceuticals a good buy?
Yes, according to 3 Wall Street analysts, Infinity Pharmaceuticals (INFI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of INFI's total ratings.